Search results for "osteonecrosi"

showing 10 items of 207 documents

Surgical treatment of medication-related osteonecrosis of the jaws with addiction of L-PRF: preliminary results

2018

Surgical treatment medication-related osteonecrosis of the jaws L-PRF
researchProduct

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

2016

Introduction: Osteonecrosis of the jaw (ONJ) is a clinically important, potentially painful and debilitating condition, which can affect the quality of life of cancer patients. Since 2003, ONJ appeared as a Bisphosphonate(BP)-related class effect, and the term Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) was widespread. Areas Covered: Under discussion in this review is the fact that ONJ cases have been reported after treatment including antiangiogenic agents and other “targeted therapy”, with and without BPs. Consequently, the comprehensive term Medication-Related Osteonecrosis of the Jaw (MRONJ) has been introduced. The clinical aspects and the prognosis of ONJ associated with t…

aflibercept; bevacizumab; Bisphosphonate; Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ); denosumab; everolimus; Medication-Related Osteonecrosis of the Jaw (MRONJ); Osteonecrosis of the jaw (ONJ); sunitinib; temsirolimus; Angiogenesis Inhibitors; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Humans; Jaw Diseases; Molecular Targeted Therapy; Neoplasms; Osteonecrosis; Quality of Life; Risk Assessment; Pharmacology (medical)Oncologysunitinibmedicine.medical_treatmentAngiogenesis InhibitorstemsirolimuTargeted therapyAntineoplastic Agent0302 clinical medicineNeoplasmsPharmacology (medical)Molecular Targeted TherapyJaw DiseaseafliberceptOsteonecrosisGeneral MedicineDenosumab030220 oncology & carcinogenesisOsteonecrosiBisphosphonate-Associated Osteonecrosis of the JawAngiogenesis InhibitorHumanmedicine.drugmedicine.medical_specialtyBevacizumabAntineoplastic AgentsbevacizumabRisk AssessmentBisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)Medication-Related Osteonecrosis of the Jaw (MRONJ)03 medical and health sciencesInternal medicinemedicineBisphosphonateHumansBisphosphonate-associated osteonecrosis of the jawbusiness.industryeverolimuCancerdenosumab030206 dentistryBisphosphonatemedicine.diseaseOsteonecrosis of the jaw (ONJ)Quality of LifeNeoplasmJaw DiseasesOsteonecrosis of the jawbusinessJaw DiseasesExpert Opinion on Drug Safety
researchProduct

Findings of osteonecrosis of the jaw under combined bisphosphonate and antiangiogenic therapies: an emergent problem?

2011

antiangiogenic agentsSettore MED/09 - Medicina InternaOsteonecrosis of the jawSettore MED/28 - Malattie OdontostomatologicheSettore BIO/14 - Farmacologiabisphosponate
researchProduct

Bisfosfonati: utilità terapeutiche e reazioni avverse di interesse odontostomatologico

2020

I bifosfonati hanno la capacità di modulare il turnover osseo, controllare e ridurre il rimodellamento in corso di riassorbimento.Il loro meccanismo d’azione si basa sulla capacità di inibire il riassorbimento osseo mediato dagli osteoclasti.

bisfosfonati osteonecrosi ossa mascellari da farmaci reazione avversa
researchProduct

Significance of immunohistochemistry biomarkers in prediction of malignant transformation of oral lichen planus

2022

Background: Oral lichen planus (OLP) is a chronic inflammatory disorder with increased risk for malignant transformation. Biomarker validation is a pivotal step in moving newly discovered biomarkers towards clinical implementation. We performed a systematic review of studies on biomarkers related to OLP, wherein biomarkers have been described in at least two independent studies. Our aim was to determine whether any of these biomark-ers might be promising in predicting the increased risk of malignant transformation of OLP. Material and Methods: We searched the following databases until August 2021: PUBMED, EMBASE, and Web of Science. Due to high heterogeneity, a qualitative rather than quant…

bisphosphonate osteonecrosisp53malignant transformationP21bone densitybiomarkerscomputed tomographycervical vertebraeImmunohistochemistryCell Transformation NeoplasticjawOtorhinolaryngologySDG 3 - Good Health and Well-beingProliferating Cell Nuclear AntigenOral lichen planusBCl-2Humans/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingPCNAMouth NeoplasmsSurgeryGeneral DentistryUNESCO:CIENCIAS MÉDICASLichen Planus OralMedicina oral patologia oral y cirugia bucal
researchProduct

Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020

2020

The Medication-Related Osteonecrosis of Jaws (MRONJ) diagnosis process and its prevention play a role of great and rising importance, not only on the Quality of Life (QoL) of patients, but also on the decision-making process by the majority of dentists and oral surgeons involved in MRONJ prevention (primary and secondary). The present paper reports the update of the conclusions from the Consensus Conference—held at the Symposium of the Italian Society of Oral Pathology and Medicine (SIPMO) (20 October 2018, Ancona, Italy)—after the newest recommendations (2020) on MRONJ were published by two scientific societies (Italian Societies of Maxillofacial Surgery and Oral Pathology and Medicine, SI…

bisphosphonateOral SurgeonHealth Toxicology and Mutagenesislcsh:MedicineMRONJantiangiogenic agents; antiresorptive drugs; bisphosphonates; cancer; denosumab; dentistry; MRONJ; oral surgery; osteoporosis; prevention models; bisphosphonate-associated osteonecrosis of the jaw; bone density conservation agents; diphosphonates; humans; Italy; quality of life0302 clinical medicineprevention modelCancerantiangiogenic agentsdentistryBone Density Conservation AgentsDiphosphonatesConference ReportBisphosphonatesAntiresorptive DrugsDenosumabItaly030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawDenosumabmedicine.drugoral surgerymedicine.medical_specialtyOral surgery03 medical and health sciencesOral surgeryAntiangiogenic agentsOral and maxillofacial pathologymedicinecancerHumansantiangiogenic agentantiresorptive drugsIntensive care medicinePrevention modelsbisphosphonatesantiresorptive drugAntiangiogenic agentsbusiness.industrylcsh:RPublic Health Environmental and Occupational Healthdenosumab030206 dentistrymedicine.diseaseosteoporosisAntiresorptive drugsDentistryOsteoporosisprevention modelsbusinessAntiangiogenic agents; Antiresorptive drugs; Bisphosphonates; Cancer; Denosumab; Dentistry; MRONJ; Oral surgery; Osteoporosis; Prevention models
researchProduct

Medication related osteonecrosis of the jaw (MRONJ)

2018

business.industryOral and maxillofacial pathologyMedicineDentistrybusinessOsteonecrosis of the jawmedicine.disease
researchProduct

Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro

2010

Oral Diseases (2011) 17, 194–199 Objectives:  Bisphosphonate-associated osteonecrosis of the jaw (BP-ONJ) is a side effect in patients being treated with bisphosphonates. The bisphosphonates most often associated with BP-ONJ are the highly potent nitrogen-containing bisphosphonates, e.g. pamidronate or zoledronate. In terms of BP-ONJ aetiology, several theories are being discussed: inhibition of bone remodelling, effect on soft tissues, and antiangiogenic effect of bisphosphonates. The aim of this in vitro study was to investigate the effect of different potent bisphosphonates on osteoblasts, fibroblasts and human umbilicord vein endothelial cells (HUVEC). Materials and methods:  Three nitr…

business.industrymedicine.medical_treatmentOsteoblastCell migrationBisphosphonatemedicine.diseaseIbandronic acidZoledronic acidmedicine.anatomical_structureOtorhinolaryngologyImmunologymedicineCancer researchViability assaybusinessWound healingOsteonecrosis of the jawGeneral Dentistrymedicine.drugOral Diseases
researchProduct

Tomographic study of Jaw bone changes in patients with bisphosphonate-related osteonecrosis

2020

Background Bisphosphonates (BP) are synthetic pyrophosphate-like substances with antiresorptive properties and specifically affect osteoclastic activity. In 2007, the American Association of Oral and Maxillofacial Surgeons (AAOMS) defined diagnostic criteria for Osteonecrosis of the Jaws Associated with Bisphosponates (BRONJ). BRONJ is mainly diagnosed by clinical features, but the detection of early bone changes by imaging may help prevent and better understand the disease. The objective of this study was to evaluate maxillary changes in CBCT in patients using BP. Material and methods All included patients were diagnosed with osteonecrosis and received bisphosphonate drugs in the last ten …

business.industrymedicine.medical_treatmentResearchOsteoporosisMandibleDentistryCancer030206 dentistryBisphosphonatemedicine.disease:CIENCIAS MÉDICAS [UNESCO]MANDÍBULALesion03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASMedicinePeriodontal fiberOdontostomatology for the Disabled or Special PatientsStage (cooking)medicine.symptombusinessOsteonecrosis of the jawGeneral Dentistry
researchProduct

Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaww (Letter to Editor)

2009

guidelines/ bisphosphonat/ osteonecrosis jaww
researchProduct